Regeneron Pharmaceuticals Inc (REGN) Shares Bought by Putnam FL Investment Management Co.

Putnam FL Investment Management Co. increased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 19,344 shares of the biopharmaceutical company’s stock after acquiring an additional 306 shares during the period. Putnam FL Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $7,816,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REGN. Meiji Yasuda Asset Management Co Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 61.9% in the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,877 shares of the biopharmaceutical company’s stock valued at $1,162,000 after purchasing an additional 1,100 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the third quarter. Dimensional Fund Advisors LP now owns 177,466 shares of the biopharmaceutical company’s stock valued at $71,706,000 after purchasing an additional 5,605 shares during the last quarter. Meiji Yasuda Life Insurance Co raised its holdings in shares of Regeneron Pharmaceuticals by 46.7% in the third quarter. Meiji Yasuda Life Insurance Co now owns 3,143 shares of the biopharmaceutical company’s stock valued at $1,270,000 after purchasing an additional 1,000 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $428,000. Finally, Virtu Financial LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $236,000. 66.83% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently commented on REGN. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. TheStreet downgraded shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Tuesday, November 13th. Robert W. Baird downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Friday, August 3rd. Argus reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 13th. Finally, Canaccord Genuity increased their target price on shares of Regeneron Pharmaceuticals from $304.00 to $390.00 and gave the company a “hold” rating in a report on Friday, August 3rd. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and five have given a buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $402.37.

NASDAQ REGN traded up $10.94 during trading hours on Monday, reaching $351.80. 83,221 shares of the company were exchanged, compared to its average volume of 705,115. Regeneron Pharmaceuticals Inc has a 1 year low of $281.89 and a 1 year high of $416.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. The company has a market capitalization of $36.88 billion, a PE ratio of 26.23, a price-to-earnings-growth ratio of 1.18 and a beta of 1.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The business had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the company posted $3.99 earnings per share. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals Inc will post 19.48 EPS for the current fiscal year.

In other news, Director Michael S. Brown sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, September 27th. The shares were sold at an average price of $392.26, for a total value of $784,520.00. Following the completion of the transaction, the director now owns 2,000 shares in the company, valued at $784,520. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The disclosure for this sale can be found here. Insiders sold 108,552 shares of company stock valued at $44,081,027 in the last quarter. Corporate insiders own 12.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals Inc (REGN) Shares Bought by Putnam FL Investment Management Co.” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.wkrb13.com/2018/11/26/regeneron-pharmaceuticals-inc-regn-shares-bought-by-putnam-fl-investment-management-co.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Yield Curve

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply